| BUSINESS STRATEGY |
APIs and generics are equally important. "In terms of strategy, the ideal for us would be a 50-50 split between these two activities. "Having this mix of products is critical in managing the ups and downs of the pharmaceutical business."
Manufacturers of generic APIs take a huge risk. They select a product based on the feasibility of inventing a different manufacturing route, develop the process chemistry, and assemble the drug master file--or registration dossier for European customers. Then they find buyers.
But it's not that straightforward. Finding a reliable source of raw materials is fundamental
|